Adults 11 to 18, any sex, with Tobacco Use Behavior. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Susceptibility to VapingPrimary· 4 weeks; Note that each survey completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources.
During the course of the study surveys reviewed. This outcome was measured using a binary form of the susceptibility to vaping scale, which aims at measuring intention to vape. Scores were 0 (non-susceptible) or 1 (susceptible). A score of 1 has a worse value than a score of 0.
Group
Value
95% CI
ASPIRE Group
66
GSA-ASPIRE-Network Group
118
Susceptibility to Using Conventional TobaccoPrimary· 4 weeks; Note that each survey completion has a window of 2 weeks, taking into account site availability, presence of students, holidays, and site resources.
During the course of the study surveys reviewed. This outcome was measured using a binary form of the susceptibility to smoking scale, which aims at measuring intention to use conventional tobacco. Scores were 0 (non-susceptible) or 1 (susceptible). A score of 1 has a worse value than a score of 0. The measure combines susceptibility to using cigarettes, cigars, hookah, and chewing tobacco.
Group
Value
95% CI
ASPIRE Group
63
GSA-ASPIRE-Network Group
106
Sponsor's own description
The central hypothesis of this study is that the addition of social influence strategies to a web-based program called ASPIRE will boost its success in lowering intention to use tobacco among adolescents and experiencing stronger positive social influence. The study will involve a nested group randomized controlled trial with adolescents from after-school programs and schools (e.g., the PK Yonge school) in Florida.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
· not yet recruiting
NCT07137468 — Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk
· recruiting
NCT07010081 — Using Digital Health in a Postoperative Setting After Major Surgery: Survey Study
· NA
· recruiting
NCT06962995 — Multi-Cancer Detection Observational Cohort Study
· recruiting
NCT06960499 — Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy
· not yet recruiting
Other University of Florida trials
Trials by the same sponsor.
NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
· NA
· not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia
· NA
· suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl
· Phase 2, PHASE3
· not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
· Phase 1
· not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02703597.